Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
270 USD | +0.22% | +0.39% | -6.26% |
26/04 | Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe | MT |
26/04 | Amgen to Seek European OK of Thyroid Eye Disease Drug Tepezza | DJ |
Sales 2024 * | 32.95B 2,747B | Sales 2025 * | 34.14B 2,847B | Capitalization | 145B 12,074B |
---|---|---|---|---|---|
Net income 2024 * | 6.12B 510B | Net income 2025 * | 7.56B 630B | EV / Sales 2024 * | 5.8 x |
Net Debt 2024 * | 46.47B 3,875B | Net Debt 2025 * | 40.28B 3,359B | EV / Sales 2025 * | 5.42 x |
P/E ratio 2024 * |
23.5
x | P/E ratio 2025 * |
18.2
x | Employees | 26,700 |
Yield 2024 * |
3.43% | Yield 2025 * |
3.72% | Free-Float | 99.75% |
Latest transcript on Amgen Inc.
1 day | +0.22% | ||
1 week | +0.39% | ||
Current month | -5.04% | ||
1 month | -4.18% | ||
3 months | -13.40% | ||
6 months | +0.10% | ||
Current year | -6.26% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 01/06/01 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 23/19/23 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | 18/12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 03/17/03 |
Ellen Kullman
BRD | Director/Board Member | 68 | 14/16/14 |
Robert Williams
BRD | Director/Board Member | 75 | 17/14/17 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
7.84% | 0 M€ | 0.00% | - | |
7.63% | 0 M€ | 0.00% | - | |
5.08% | 120 M€ | +12.61% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 270 | +0.22% | 2,436,959 |
25/24/25 | 269.4 | -1.33% | 1,794,024 |
24/24/24 | 273 | -0.19% | 2,467,127 |
23/24/23 | 273.5 | +0.60% | 2,493,321 |
22/24/22 | 271.9 | +1.11% | 2,165,755 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.26% | 145B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-11.77% | 144B |
- Stock Market
- Equities
- AMGN Stock